This photo shows a general view of the offices of British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca PLC in Macclesfield, Cheshire on July 21, 2020. (PAUL ELLIS / AFP)

CHENGDU - Multinational pharmaceutical giant AstraZeneca plans to establish a traditional Chinese medicine industry innovation center in southwest China's Sichuan Province, according to local authorities.

AstraZeneca signed an online agreement with the Chengdu Hi-Tech Industrial Development Zone to jointly launch the center that will incubate and empower the modern TCM industry, according to the zone.

AstraZeneca settled its western China headquarters in the Chengdu Hi-Tech Zone in November 2020. The regional headquarters began operations in September last year

The center integrates an academic-led research institution and platforms that offer TCM industry support, business modernization and clinical commercialization. 

AstraZeneca settled its western China headquarters in the Chengdu Hi-Tech Zone in November 2020. The regional headquarters began operations in September last year.

ALSO READ: Multinationals boost presence in country

The Chengdu Hi-Tech Zone has over 3,000 medical enterprises. In the first quarter of 2022, the industrial output and industrial added value of major medical and healthcare companies in the zone respectively rose 14.2 percent and 8 percent from the same period last year.

AstraZeneca entered China in 1993 and achieved a total revenue of $37.4 billion worldwide in 2021, with $6 billion coming from the Chinese market.

READ MORE: AstraZeneca COVID-19 drug neutralizes Omicron sub-variants

Headquartered in London, AstraZeneca focuses on the treatment of respiratory, cardiovascular, metabolic, renal and digestive diseases.